Tafamidis for treating transthyretin amyloidosis with cardiomyopathy - guidance (TA696)

Tafamidis is not recommended for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults. There is not enough evidence that it would reduce diagnosis delays and uncertainty about how long the treatment works after it is stopped.

Source:

National Institute for Health and Care Excellence